Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.54 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.42 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.42 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.42 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6785583 | 1.00 | CYP1A2 (0.54) | CYP1A2EPHX1SLC6A2TAAR1MAOA | |
| Hydrochloric Acid SCHEMBL6791172 | 0.98 | CYP1A2 (0.53) | CYP1A2EPHX1SLC6A2TAAR1MAOA | |
| SCHEMBL7143643 | 0.90 | CYP1A2 (0.45) | CYP1A2EPHX1TAAR1ALDH1A1SMN1; SMN2 | |
| Trifluoroacetic Acid SCHEMBL29484058 | 0.88 | CYP1A2 (0.44) | CYP1A2ANPEPALPIPKMPTGS1 | |
| SCHEMBL13919546 | 0.86 | LTA4H (0.53) | CYP1A2SLC6A2MAOASLC6A3SIGMAR1 | |
| SCHEMBL11528941 | 0.83 | CYP1A2 (0.42) | CYP1A2EPHX1SLC6A2TAAR1MAOA | |
| SCHEMBL6222556 | 0.83 | CYP1A2 (0.41) | CYP1A2EPHX1TAAR1MAOACYP2A6 | |
| SCHEMBL22885976 | 0.80 | CYP1A2 (0.42) | CYP1A2EPHX1SLC6A2TAAR1MAOA | |
| SCHEMBL19354261 | 0.80 | IDO1 (0.43) | CYP1A2EPHX1L3MBTL1ALPIPKM | |
| SCHEMBL19354535 | 0.80 | IDO1 (0.43) | CYP1A2EPHX1L3MBTL1ALPIPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12612429-B2 | Derivatives of dolaproine-dolaisoleuine peptides | AGENSYS, INC. (US) | 2026-04-28 | — | — | US | disclosed |
| US-20220204557-A1 | DERIVATIVES OF DOLAPROINE-DOLAISOLEUINE PEPTIDES | AGENSYS, INC. (US) | 2022-06-30 | — | — | US | disclosed |
| US-11312748-B2 | Derivatives of dolaproine-dolaisoleucine peptides | AGENSYS, INC. (US) | 2022-04-26 | — | — | US | disclosed |
| US-8877815-B2 | Substituted carbamoylcycloalkyl acetic acid derivatives as NEP | NOVARTIS AG (CH) | 2014-11-04 | — | — | US | disclosed |
| US-20120122764-A1 | SUBSTITUTED CARBAMOYLCYCLOALKYL ACETIC ACID DERIVATIVES AS NEP | NOVARTIS AG (CH) | 2012-05-17 | — | — | US | disclosed |
| US-5294631-A | Substituted benzimidazoles useful as angiotension II receptor antagonists | SMITHKLINE BEECHAM CORPORATION (US) | 1994-03-15 | — | — | US | disclosed |
| US-5234917-A | Hypotensive agent, treatment of renal failure or glaucoma | SMITHKLINE BEECHAM CORPORATION | 1993-08-10 | — | — | US | disclosed |
| EP-0525129-A4 | SUBSTITUTED BENZIMIDAZOLES | — | 1993-03-24 | — | — | EP | disclosed |
| EP-0525129-A1 | SUBSTITUTED BENZIMIDAZOLES | SMITHKLINE BEECHAM CORPORATION (US) | 1993-02-03 | — | — | EP | disclosed |
| WO-1991016313-A1 | SUBSTITUTED BENZIMIDAZOLES | SMITHKLINE BEECHAM CORPORATION (US) | 1991-10-31 | — | — | WO | disclosed |
| EP-0437103-A2 | Substituted 5-(alkyl)carboxamide imidazoles | SMITHKLINE BEECHAM CORPORATION (US) | 1991-07-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220204557-A1 | DERIVATIVES OF DOLAPROINE-DOLAISOLEUINE PEPTIDES | DDOST, VIP, THPO | CYP1A2 4496/4885EPHX1 2370/4885SLC6A2 4390/4885 |
| US-12612429-B2 | Derivatives of dolaproine-dolaisoleuine peptides | DDOST, NGLY1, GRPR | CYP1A2 4628/4885EPHX1 2167/4885SLC6A2 4276/4885 |
| US-20120122764-A1 | SUBSTITUTED CARBAMOYLCYCLOALKYL ACETIC ACID DERIVATIVES AS NEP | MME, REN, ECE1 | CYP1A2 1025/4885EPHX1 389/4885SLC6A2 837/4885 |
| US-11312748-B2 | Derivatives of dolaproine-dolaisoleucine peptides | VIP, DDOST, DNPEP | CYP1A2 4792/4885EPHX1 4050/4885SLC6A2 4228/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.